Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (244)	1/29/2000 1:45:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

I should point out that the David Waltz trial at Harvard is also tgAAV--and that doses are listed as high as 10^13 and that Purpose of additional cohort is to generate additional safety and kinetic data. If we go back to the H&Q presentation, we will find that one of the slides showed data points with one copy/cell at 10^5. There was something about IL-8 in there, hey--maybe gene therapy and asthma someday? ____ Regarding tgDCC-E1A... For the downregulation of HER2/neu, two of the six curves on the expression graph decreased awfully close to zero percent expression. The E1A Survival chart, looks impressive, check it out. Sensitizes tumors in vivo--Multicenter PII w/ chemo in 2000 (w/ out chemo was 1999) On Hemophillia A--something about proprietary positon for delivery w/ single AAV, I'd have to go back and check again. And finally for tgLPD-E1A, a very nice graph showing combo w/ paclitaxel. I'd hoped we would have some more from biowa by now, --naturally I'm a little nervous at the stock action this week--so I'll step up to the plate and try and start things up here. For those interested, the MS Powerpoint presentation seems to work fine now--I had to download the software, and it took two tries, but worked fine. Sorry I did not post more before the close of trading, but if biotech keeps getting whacked on Monday, there could still be good buying ops.